The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2023 | The role of daratumumab in combination with lenalidomide as maintenance therapy in NDMM post-autoSCT
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, comments on the addition of anti-CD38 monoclonal antibodies to lenalidomide as a post-autologous stem cell transplantation (autoSCT) maintenance strategy in newly diagnosed multiple myeloma (NDMM), highlighting clinical trials evaluating this strategy. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses – Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline and Takeda.
